These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 18977777)

  • 21. Serological analysis of patients treated with a new surgical hemostat containing bovine proteins and autologous plasma.
    Nelson PA; Powers JN; Estridge TD; Elder EA; Alea AD; Sidhu PK; Sehl LC; DeLustro FA
    J Biomed Mater Res; 2001; 58(6):710-9. PubMed ID: 11745525
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A phase 3, randomized, double-blind comparative study of the efficacy and safety of topical recombinant human thrombin and bovine thrombin in surgical hemostasis.
    Chapman WC; Singla N; Genyk Y; McNeil JW; Renkens KL; Reynolds TC; Murphy A; Weaver FA
    J Am Coll Surg; 2007 Aug; 205(2):256-65. PubMed ID: 17660072
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk and clinical significance of developing antibodies induced by topical thrombin preparations.
    Dorion RP; Hamati HF; Landis B; Frey C; Heydt D; Carey D
    Arch Pathol Lab Med; 1998 Oct; 122(10):887-94. PubMed ID: 9786349
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A safety review of topical bovine thrombin-induced generation of antibodies to bovine proteins.
    Ofosu FA; Crean S; Reynolds MW
    Clin Ther; 2009 Apr; 31(4):679-91. PubMed ID: 19446142
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recent developments in topical thrombins.
    Kessler CM; Ortel TL
    Thromb Haemost; 2009 Jul; 102(1):15-24. PubMed ID: 19572062
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Topical recombinant human thrombin in surgical hemostasis.
    Bowman LJ; Anderson CD; Chapman WC
    Semin Thromb Hemost; 2010 Jul; 36(5):477-84. PubMed ID: 20632245
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A phase 3b, open-label, single-group immunogenicity and safety study of topical recombinant thrombin in surgical hemostasis.
    Singla NK; Ballard JL; Moneta G; Randleman CD; Renkens KL; Alexander WA
    J Am Coll Surg; 2009 Jul; 209(1):68-74. PubMed ID: 19651065
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Acquired coagulation factor inhibitors in children after topical bovine thrombin exposure.
    Savage WJ; Kickler TS; Takemoto CM
    Pediatr Blood Cancer; 2007 Dec; 49(7):1025-9. PubMed ID: 16526049
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunologic impact and clinical outcomes after surgical exposure to bovine thrombin.
    Ortel TL; Mercer MC; Thames EH; Moore KD; Lawson JH
    Ann Surg; 2001 Jan; 233(1):88-96. PubMed ID: 11141230
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antigenic (immunogenic) profiling of bovine thrombin and its purified forms.
    Walenga JM; Bick RL; Messmore HL
    Clin Appl Thromb Hemost; 2008 Apr; 14(2):133-4. PubMed ID: 18372275
    [No Abstract]   [Full Text] [Related]  

  • 31. Preclinical safety of recombinant human thrombin.
    Heffernan JK; Ponce RA; Zuckerman LA; Volpone JP; Visich J; Giste EE; Jenkins N; Boster D; Pederson S; Knitter G; Palmer T; Wills M; Early RJ; Rogge MC
    Regul Toxicol Pharmacol; 2007 Feb; 47(1):48-58. PubMed ID: 16971028
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Achieving hemostasis in the surgical field.
    Boucher BA; Traub O
    Pharmacotherapy; 2009 Jul; 29(7 Pt 2):2S-7S. PubMed ID: 19558278
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antibody induced coagulopathy from bovine thrombin use during partial nephrectomy.
    Pavlovich CP; Battiwalla M; Rick ME; Walther MM
    J Urol; 2001 May; 165(5):1617. PubMed ID: 11342931
    [No Abstract]   [Full Text] [Related]  

  • 34. Acquired factor V inhibitor: a common and avoidable complication of topical bovine thrombin application.
    Kirkeby KM; Aronowitz P
    Am J Med; 2005 Jul; 118(7):805. PubMed ID: 15989925
    [No Abstract]   [Full Text] [Related]  

  • 35. Topical thrombins: benefits and risks.
    Lomax C; Traub O
    Pharmacotherapy; 2009 Jul; 29(7 Pt 2):8S-12S. PubMed ID: 19558279
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Iatrogenic immunization with bovine thrombin: a mechanism for prolonged thrombin times after surgery.
    Flaherty MJ; Henderson R; Wener MH
    Ann Intern Med; 1989 Oct; 111(8):631-4. PubMed ID: 2802417
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immune responses associated with perioperative exposure and reexposure to topical bovine thrombin do not impair hemostasis.
    Paterson CA; Pixton GC; Proskin HM; Massaro JM; Morasch M; Cronstein B; Fareed J; Ofosu FA
    Clin Appl Thromb Hemost; 2011; 17(6):620-32. PubMed ID: 21596694
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A gelatin-thrombin matrix for hemostasis after endoscopic sinus surgery.
    Woodworth BA; Chandra RK; LeBenger JD; Ilie B; Schlosser RJ
    Am J Otolaryngol; 2009; 30(1):49-53. PubMed ID: 19027513
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Thrombin products: economic impact of immune-mediated coagulopathies and practical formulary considerations.
    Voils SA
    Pharmacotherapy; 2009 Jul; 29(7 Pt 2):18S-22S. PubMed ID: 19558281
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of antibodies to thrombin and factor V with recurrent bleeding in a patient exposed to topical bovine thrombin.
    Zehnder JL; Leung LL
    Blood; 1990 Nov; 76(10):2011-6. PubMed ID: 2242423
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.